Jacobs Levy Equity Management
PEAR

Jacobs Levy Equity Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Jacobs Levy Equity Management’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-120,237
Closed -$30.7K – 1119
2023
Q1 		$30.7K Buy
+120,237
New +$109K ﹤0.01% 943

Jacobs Levy Equity Management's PEAR Position: Q2 2023 in Review

Jacobs Levy Equity Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 120,237 shares — an estimated $30.7K sold.

Jacobs Levy Equity Management first reported a position in PEAR in Q1 2023 and held it in 1 quarter. The position peaked at $30.7K in Q1 2023. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

  • Jacobs Levy Equity Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 120,237 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $30.7K.
  • Jacobs Levy Equity Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2023 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $30.7K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2023, filed 14 Aug 2023.